



The Dow Chemical Company
727 Norristown Rd.
P.O. Box 904
Spring House, PA 19477
U.S.A.

July 21, 2009

Community Advisory Council Members
at
Spring House Technical Center

Re: Updates to Spring House Epidemiological Study

Dear Member:

I would like to take this opportunity to introduce myself and to let you know about some recent updates and enhancements to the Spring House epidemiology study, which is being conducted by the University of Minnesota.

As some of you may know, since 2002, Rohm and Haas has been investigating concerns about the incidence of brain cancer at the Spring House Technical Center. Initial epidemiological studies have not found an association between the Spring House workplace and brain cancer, but we have asked the University of Minnesota, a pre-eminent institution with particular expertise in workplace health studies, to review and complete its own investigation. We believe this decision serves all our stakeholders, including our Spring House employees.

As the chief medical officer of The Dow Chemical Company, I want to emphasize that Dow has a strong commitment to the health of its people and takes this issue seriously. We have been actively assessing how to assure that the process is transparent and ensure that the University of Minnesota study team is provided with the information and access to subject matter experts and resources needed to complete its work and make a comprehensive and accurate evaluation in a timely manner.

In March 2008, Rohm and Haas contracted with the University of Minnesota, a NIOSH-funded research and education center, to complete an epidemiological study at the site. That study is on track and is expected to be completed by mid-2010

We have many priorities as a company going forward but none more important than employee health and safety. We have talked with company representatives as well as the staff at the University of Minnesota. Two actions were announced today that will strengthen and enhance the efforts already underway.

First, the University of Minnesota has decided to form a Science Advisory Board. The University's announcement is attached for your background.

Second, Dow will expand the stakeholder engagement process to more directly include all current and former employees. Dr. Eileen Bonner, previously medical director for Rohm and Haas and now Delaware Valley Regional Health Director for Dow, will be available to discuss health questions, including those about the study, with employees. She will forward questions or concerns to the University of Minnesota or the Science Advisory Board, as appropriate.

We will continue to brief you on the study as it progresses.

If you have any questions, please don't hesitate to contact Dr. Bonner or myself at cbaase@dow.com or by telephone at: 989-636-6542.

Sincerely,



Catherine M. Baase, M.D.
Chief Medical Officer
The Dow Chemical Company